The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.

NCT07090629 | Completed

• 1 other identifier: 2024/CHU/21
• Study Type: observational
• Target: 126
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients without familial partial lipodystrophy who were assessed for their cardiovascular risk using coronary artery calcification scoring between 2016 and 2024.

Conditions

High Cholesterol; Lipodystrophy, Familial Partial; Diabetes

Keywords

coronary calcium score; epicardial adipose tissue; cardiovascular risk scoring; lipodystrophy

Outcome Measures

Primary Outcomes (1)

• Epicardial adipose tissue volume

  in mL

  at inclusion

Study Arms (2)

Familial Partial Lipodystrophy, Type 2 (FPLD)

Adult patients with a confirmed genetic diagnosis of lipodystrophy

Other: Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring

Control group of patients at high cardiovascular risk (CTL)

Patients without Familial Partial Lipodystrophy

Other: Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring

Interventions

Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring OTHER

Epicardial adipose tissue measurement

Control group of patients at high cardiovascular risk (CTL); Familial Partial Lipodystrophy, Type 2 (FPLD)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023

You may qualify if:

• Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023

You may not qualify if:

• None

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead
• Aix Marseille Université: collaborator
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator
• Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement: collaborator

Study Sites (1)

CHU de La Réunion

Saint-Pierre, Reunion

Location

MeSH Terms

Conditions

Hypercholesterolemia; Lipodystrophy, Familial Partial; Diabetes Mellitus; Lipodystrophy

Condition Hierarchy (Ancestors)

Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Laminopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Metabolic; Skin Diseases; Skin and Connective Tissue Diseases; Lipid Metabolism, Inborn Errors; Glucose Metabolism Disorders; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2025
• First Posted: July 29, 2025
• Study Start: May 6, 2024
• Primary Completion: December 29, 2024
• Study Completion: March 21, 2025
• Last Updated: July 31, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

RE (1)